With 0.15 million shares changed hands, the volume of the stock remained lighter than its average volume of 0.25 million shares. During the session, the Biotechnology company that operates in wider Healthcare sector, reached to the highest price of $2.1 whereas the lowest price it dropped to was $1.99. The 52-week range on MAIA shows that it touched its highest point at $5.99 and its lowest point at $1.17 during that stretch. It currently has a 1-year price target of $14.00. Beta for the stock currently stands at 0.23.
Price Performance and Earnings:
Stock performance is one of the indicators that investors use to determine whether they will profit from a stock. The price performance of MAIA was down-trending over the past week, with a drop of -5.66%, but this was down by -9.09% over a month. Three-month performance dropped to -20.95% while six-month performance fell -41.69%. The stock gained 35.14% in the past year, while it has gained 1.01% so far this year. A look at the trailing 12-month EPS for MAIA yields -1.34 with Next year EPS estimates of -1.35. For the next quarter, that number is -0.35. This implies an EPS growth rate of -7.69% for this year and 16.15% for next year.
Float and Shares Shorts:
At present, 23.97 million MAIA shares are outstanding with a float of 21.06 million shares on hand for trading. On 2024-10-31, short shares totaled 0.66 million, which was 276.0 higher than short shares on 1727654400. In addition to Dr. Vlad Vitoc M.B.A., M.D. as the firm’s Co-Founder, President, CEO & Chairman of the Board of Directors, Mr. Jeffrey C. Himmelreich serves as its Head of Finance.
Institutional Ownership:
Through their ownership of 0.075100005 of MAIA’s outstanding shares, institutional investors have minority control over the company.
An Overview of Recent Financials:
Understanding a company as a customer does not mean you will understand it as an investor. The wise investor uses quantitative research to analyze metrics such as revenue, net income, and earnings. In its fiscal quarter reported on 2024-06-30, MAIA reported revenue of $0.0 and operating income of -$4173270.0. The EBITDA in the recently reported quarter was -$4067188.0 and diluted EPS was -$0.11.
Analysts Ratings:
In the same way, a target price assigned to a stock can also reveal much about its potential. With MAIA analysts setting a high price target of 14.0 and a low target of 11.25, the average target price over the next 12 months is 12.625. Based on these targets, MAIA could surge 600.0% to reach the target high and rise by 462.5% to reach the target low. Reaching the average price target will result in a growth of 531.25% from current levels.
Analysts have provided yearly estimates in a range of -$1.61 being high and -$1.61 being low. For MAIA, this leads to a yearly average estimate of -$1.61.
